Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.
Priscilla Kaliopi BrastianosErin L TwohyElizabeth R GerstnerTimothy J KaufmannA John IafrateJochen K LennerzSuriya JeyapalanDavid E PiccioniVarun V MongaCamilo E FadulDavid SchiffJennie W TaylorSajeel A ChowdharyChetan BettegowdaGeorge AnsstasMacarena Ines de la FuenteMark D AndersonNicole ShonkaDenise DamekJose CarrilloLara J Kunschner-RonanRekha ChaudharyKurt A JaeckleFrancis M SenecalThomas J KaleyTara MorrisonAlissa A ThomasMary R WelchFabio IwamotoDavid CachiaAdam L CohenShivangi VoraMichael V KnoppIan F DunnPriya U KumthekarJann SarkariaSusan GeyerXiomara W CarreroMaria Martinez-LageDaniel P CahillPaul D BrownCaterina GianniniSandro SantagataFrederick G BarkerEvanthia GalanisPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
-mutated meningiomas, compared with historical controls. The criteria for promising activity were met, and FAK inhibition warrants further evaluation for this patient population.